METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS

1 . A method of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof, comprising:

administering to the patient a therapeutically effective amount of the VMAT2 inhibitor and

informing the patient or a medical care worker that co-administration of a strong cytochrome P450 3A4 (CYP3A4) inducer is not recommended.

2 . The method of claim 1 , wherein the patient or medical care worker is informed that co-administration of the strong CYP3A4 inducer should be avoided or discontinued.

3 . A method of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer, comprising:

discontinuing treatment of the strong CYP3A4 inducer and then

administering the VMAT2 inhibitor to the patient, thereby avoiding the use of the VMAT2 inhibitor in combination with the strong CYP3A4 inducer.

4 . The method of any one of claims 1 to 3 , wherein the strong CYP3A4 inducer is chosen from nevirapine, pentobarbital, phenytoin, lumacaftor, rifabutin, rifampicin, carbamazepine, fosphenytoin, phenobarbital, primidone, primidone, enzalutamide, mitotane, and St. John's Wort.

5 . The method of claim 4 , wherein the strong CYP3A4 inducer is chosen from rifampicin, carbamazepine, phenytoin, and St. John's Wort.

6 . The method of claim 5 , wherein the strong CYP3A4 inducer is rifampicin.

7 . The method of any one of claims 1 to 6 , wherein the VMAT2 inhibitor is administered to the patient to treat a neurological or psychiatric disease or disorder.

8 . The method of claim 7 , wherein the neurological or psychiatric disease or disorder is a hyperkinetic movement disorder, mood disorder, bipolar disorder, schizophrenia, schizoaffective disorder, mania in mood disorder, depression in mood disorder, treatment-refractory obsessive compulsive disorder, neurological dysfunction associated with Lesch-Nyhan syndrome, agitation associated with Alzheimer's disease, Fragile X syndrome or Fragile X-associated tremor-ataxia syndrome, autism spectrum disorder, Rett syndrome, or chorea-acanthocytosis.

9 . The method of claim 8 , wherein the neurological or psychiatric disease or disorder is a hyperkinetic movement disorder.

10 . The method of claim 9 , wherein the hyperkinetic movement disorder is tardive dyskinesia.

11 . The method of claim 9 , wherein the hyperkinetic movement disorder is Tourette's syndrome.

12 . The method of claim 9 , wherein the hyperkinetic movement disorder is Huntington's disease.

13 . The method of claim 9 , wherein the hyperkinetic movement disorder is tics.

14 . The method of claim 9 , wherein the hyperkinetic movement disorder is chorea associated with Huntington's disease.

15 . The method of claim 9 , wherein the hyperkinetic movement disorder is ataxia, chorea, dystonia, Huntington's disease, myoclonus, restless leg syndrome, or tremors.

16 . The method of any one of claims 1 to 15 , wherein the VMAT2 inhibitor is administered orally.

17 . The method of any one of claims 1 to 16 , wherein the VMAT2 inhibitor is administered in the form of a tablet or capsule.

18 . The method of any one of claims 1 to 17 , wherein the VMAT2 inhibitor is administered with or without food.

19 . The method of any one of claims 1 to 18 , wherein the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt and/or isotopic variant thereof.

20 . The method of claim 19 , wherein the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt thereof.

21 . The method of claim 20 , wherein the VMAT2 inhibitor is a valbenazine tosylate salt.

22 . The method of claim 21 , wherein the VMAT2 inhibitor is a ditosylate salt of valbenazine.

23 . The method of claim 19 , wherein the VMAT2 inhibitor is an isotopic variant that is L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d 3 )-3-(2-methylpropyl)-2H-benzo[α]quinolizin-2-yl ester or a pharmaceutically acceptable salt thereof.

24 . The method of any one of claims 1 to 23 , wherein the VMAT2 inhibitor is administered in an amount equivalent to between about 20 mg and about 160 mg of valbenazine free base.

25 . The method of claim 24 , wherein the VMAT2 inhibitor is administered in an amount equivalent to about 20 mg of valbenazine free base.

26 . The method of claim 24 , wherein the VMAT2 inhibitor is administered in an amount equivalent to about 40 mg of valbenazine free base.

27 . The method of claim 24 , wherein the VMAT2 inhibitor is administered in an amount equivalent to about 60 mg of valbenazine free base.

28 . The method of claim 24 , wherein the VMAT2 inhibitor is administered in an amount equivalent to about 80 mg of valbenazine free base.

29 . The method of claim 24 , wherein the VMAT2 inhibitor is administered in an amount equivalent to about 120 mg of valbenazine free base.

30 . The method of any one of claims 1 to 23 , wherein the VMAT2 inhibitor is administered for a first period of time in a first amount and then the amount is increased to a second amount.

31 . The method of claim 30 , wherein the first period of time is a week.

32 . The method of claim 30 or 31 wherein the first amount is equivalent to about 40 mg of valbenazine free base.

33 . The method of any one of claims 30 to 32 , wherein the second amount is equivalent to about 80 mg of valbenazine free base.

34 . The method of any one of claims 1 to 23 , wherein the VMAT2 inhibitor is administered in an amount sufficient to achieve a maximal blood plasma concentration (C max ) of (+)-α-DHTBZ of between about 15 ng to about 60 ng per mL plasma and a minimal blood plasma concentration (C min ) of (+)-α-DHTBZ of at least 15 ng per mL plasma over an 8 hour period.

35 . The method of any one of claims 1 to 23 , wherein the VMAT2 inhibitor is administered in an amount sufficient to achieve a maximal blood plasma concentration (C max ) of (+)-α-DHTBZ of between about 15 ng to about 60 ng per mL plasma and a minimal blood plasma concentration (C min ) of approximately between about at least 33%-50% of the C max over a 12 hour period.

36 . The method of any one of claims 1 to 23 , wherein the VMAT2 inhibitor is administered in an amount sufficient to achieve: (i) a therapeutic concentration range of about 15 ng to about 60 ng of (+)-α-DHTBZ per mL plasma; and (ii) a threshold concentration of at least 15 ng (+)-α-DHTBZ per mL plasma over a period of about 8 hours to about 24 hours.

37 . The method of any one of claims 1 to 18 , wherein the VMAT2 inhibitor is (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,1 1b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-01, or a pharmaceutically acceptable salt and/or isotopic variant thereof.

38 . The method of claim 37 , wherein the VMAT2 inhibitor is (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt thereof.

39 . The method of claim 37 , wherein the VMAT2 inhibitor is an isotopic variant that is (+)-α-3-isobutyl-9,10-di(methoxy-d 3 )-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol or a pharmaceutically acceptable salt thereof.

40 . A composition for treating a patient in need of a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, comprising a therapeutically effective amount of the VMAT2 inhibitor,

wherein the patient or a medical care worker is informed that co-administration of a strong cytochrome P450 3A4 (CYP3A4) inducer is not recommended.

41 . The composition of claim 40 , wherein the patient or medical care worker is informed that co-administration of the strong CYP3A4 inducer should be avoided or discontinued.

42 . A composition for treating a patient in need of a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, and being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer, comprising

the VMAT2 inhibitor,

wherein treatment of the strong CYP3A4 inducer is discontinued prior to administration of the composition to the patient, thereby avoiding the use of the composition in combination with the strong CYP3A4 inducer.

43 . The composition of any one of claims 40 to 42 , wherein the strong CYP3A4 inducer is chosen from nevirapine, pentobarbital, phenytoin, lumacaftor, rifabutin, rifampicin, carbamazepine, fosphenytoin, phenobarbital, primidone, primidone, enzalutamide, mitotane, and St. John's Wort.

44 . The composition of claim 43 , wherein the strong CYP3A4 inducer is chosen from rifampicin, carbamazepine, phenytoin, and St. John's Wort.

45 . The composition of claim 44 , wherein the strong CYP3A4 inducer is rifampicin.

46 . The composition of any one of claims 40 to 45 , wherein the composition is for treating a neurological or psychiatric disease or disorder.

47 . The composition of claim 46 , wherein the neurological or psychiatric disease or disorder is a hyperkinetic movement disorder, mood disorder, bipolar disorder, schizophrenia, schizoaffective disorder, mania in mood disorder, depression in mood disorder, treatment-refractory obsessive compulsive disorder, neurological dysfunction associated with Lesch-Nyhan syndrome, agitation associated with Alzheimer's disease, Fragile X syndrome or Fragile X-associated tremor-ataxia syndrome, autism spectrum disorder, Rett syndrome, or chorea-acanthocytosis.

48 . The composition of claim 47 , wherein the neurological or psychiatric disease or disorder is a hyperkinetic movement disorder.

49 . The composition of claim 48 , wherein the hyperkinetic movement disorder is tardive dyskinesia.

50 . The composition of claim 48 , wherein the hyperkinetic movement disorder is Tourette's syndrome.

51 . The composition of claim 48 , wherein the hyperkinetic movement disorder is Huntington's disease.

52 . The composition of claim 48 , wherein the hyperkinetic movement disorder is tics.

53 . The composition of claim 48 , wherein the hyperkinetic movement disorder is chorea associated with Huntington's disease.

54 . The composition of claim 48 , wherein the hyperkinetic movement disorder is ataxia, chorea, dystonia, Huntington's disease, myoclonus, restless leg syndrome, or tremors.

55 . The composition of any one of claims 40 to 54 , characterized in that the composition is administered orally.

56 . The composition of any one of claims 40 to 55 , characterized in that the composition is administered in the form of a tablet or capsule.

57 . The composition of any one of claims 40 to 56 , characterized in that the composition is administered with or without food.

58 . The composition of any one of claims 40 to 57 , wherein the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt and/or isotopic variant thereof.

59 . The composition of claim 58 , wherein the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt thereof.

60 . The composition of claim 59 , wherein the VMAT2 inhibitor is a valbenazine tosylate salt.

61 . The composition of claim 60 , wherein the VMAT2 inhibitor is a ditosylate salt of valbenazine.

62 . The composition of any one of claims 40 to 61 , characterized in that the composition is administered in an amount equivalent to between about 20 mg and about 120 mg of valbenazine free base of the VMAT2 inhibitor.

63 . The composition of claim 62 , characterized in that the composition is administered in an amount equivalent to about 20 mg of valbenazine free base of the VMAT2 inhibitor.

64 . The composition of claim 62 , characterized in that the composition is administered in an amount equivalent to about 40 mg of valbenazine free base of the VMAT2 inhibitor.

65 . The composition of claim 62 , characterized in that the composition is administered in an amount equivalent to about 80 mg of valbenazine free base of the VMAT2 inhibitor.

66 . The composition of claim 62 , characterized in that the composition is administered in an amount equivalent to about 60 mg of valbenazine free base of the VMAT2 inhibitor.

67 . The composition of claim 62 , characterized in that the composition is administered in an amount equivalent to about 120 mg of valbenazine free base of the VMAT2 inhibitor.

68 . The composition of any one of claims 40 to 61 , characterized in that the composition is administered for a first period of time in a first amount of the VMAT2 inhibitor and then the amount is increased to a second amount.

69 . The composition of claim 68 , wherein the first period of time is a week.

70 . The composition of claim 68 or 69 wherein the first amount is equivalent to about 40 mg of valbenazine free base.

71 . The composition of any one of claims 68 to 70 , wherein the second amount is equivalent to about 80 mg of valbenazine free base.

72 . The composition of any one of claims 40 to 61 , characterized in that the composition is administered in an amount sufficient to achieve a maximal blood plasma concentration (C max ) of (+)-α-DHTBZ of between about 15 ng to about 60 ng per mL plasma and a minimal blood plasma concentration (C min ) of (+)-α-DHTBZ of at least 15 ng per mL plasma over an 8 hour period.

73 . The composition of any one of claims 40 to 61 , characterized in that the composition is administered in an amount sufficient to achieve a maximal blood plasma concentration (C max ) of (+)-α-DHTBZ of between about 15 ng to about 60 ng per mL plasma and a minimal blood plasma concentration (C min ) of approximately between about at least 33%-50% of the C max over a 12 hour period.

74 . The composition of any one of claims 40 to 61 , characterized in that the composition is administered in an amount sufficient to achieve: (i) a therapeutic concentration range of about 15 ng to about 60 ng of (+)-α-DHTBZ per mL plasma; and (ii) a threshold concentration of at least 15 ng (+)-α-DHTBZ per mL plasma over a period of about 8 hours to about 24 hours.

75 . The composition of claim 58 , wherein the VMAT2 inhibitor is an isotopic variant that is L-Valine, (2R,3R,11bR)-1,3,4,6,7,1 1b-hexahydro-9,10-di(methoxy-d 3 )-3-(2-methylpropyl)-2H-benzo[α]quinolizin-2-yl ester or a pharmaceutically acceptable salt thereof.

76 . The composition of any one of claims 40 to 57 , wherein the VMAT2 inhibitor is (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof.

77 . The composition of claim 76 , wherein the VMAT2 inhibitor is (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,1 1b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt thereof.

78 . The of composition claim 76 , wherein the VMAT2 inhibitor is an isotopic variant that is (+)-α-3-isobutyl-9,10-di(methoxy-d 3 )-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol or a pharmaceutically acceptable salt thereof.